Skip to content

Study · Not a test of the peptide alone · 1996

4 results

T cell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of schistosome-infected mice.

Metwali A, Elliott D, Blum AM, Li J, Sandor M, Weinstock JV

Journal of immunology (Baltimore, Md. : 1950)1 Jul 1996Cited by 9 (Europe PMC)

PMID8683124 (opens in a new tab)DOI10.4049/jimmunol.157.1.265 (opens in a new tab)PepBankPUB-08683124
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In splenocytes and granuloma cells from schistosome-infected mice, PACAP displaced radiolabeled VIP as effectively as VIP did, so most VIP receptors also bind PACAP.

    In plain wordsIn cells from infected mice, PACAP displaced VIP from its receptors as well as VIP itself did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablePACAP displacement of radiolabeled VIP binding
    Study

    mousen: not reported in source

    Schistosoma mansoni-infected mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Using a radioligand-binding assay, it was established that PACAP is as effective as VIP at displacing radiolabeled VIP from splenocytes and granuloma cells, and that most if not all VIPRs in the spleen and granulomas bind PACAP.
    1 context sentence
    Summary · context
    The objective of this study was to determine if granulomas express either VIPR1 or VIPR2.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In granulomas of schistosome-infected mice, both VIPR1 and VIPR2 mRNAs were detected.

    In plain wordsIn infected mice, liver and gut lesions called granulomas carried the genetic message for both types of VIP receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIPR1 and VIPR2 mRNA in granulomas
    Study

    mousen: not reported in source

    Schistosoma mansoni-infected mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    PCR amplification of reverse transcribed RNA determined that granulomas express both VIPR1 and VIPR2 mRNAs.
    1 context sentence
    Summary · context
    The objective of this study was to determine if granulomas express either VIPR1 or VIPR2.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    Both VIP receptor subtypes were found in granuloma CD4+ T cell lines, while T cell-depleted granuloma cells had only VIPR1 RNA.

    In plain wordsIn mice, granuloma T cell lines carried both VIP receptor types, but granuloma cells without T cells carried only one type.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIPR subtypes in granuloma CD4+ T cell lines and T cell-depleted granuloma cells
    Study

    mousen: not reported in source

    Schistosoma mansoni-infected mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Also, both receptor subtypes were amplified from several granuloma CD4+ T cell lines; yet reverse transcribed RNA from T cell-depleted, dispersed granuloma cells had only VIPR1 RNA.
    1 context sentence
    Summary · context
    The objective of this study was to determine if granulomas express either VIPR1 or VIPR2.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In mice with schistosomiasis, only VIPR1 was detected by reverse transcriptase-PCR in the thymus and spleen.

    In plain wordsIn mice, only one of the two VIP receptor types was found in the thymus and spleen.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIPR subtypes in thymus and spleen
    Study

    mousen: not reported in source

    Schistosoma mansoni-infected mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    It is notable that reverse transcriptase-PCR detected only VIPR1 in the thymus and spleen, which are organs rich in T lymphocytes.
    1 context sentence
    Summary · context
    The objective of this study was to determine if granulomas express either VIPR1 or VIPR2.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.